NasdaqCM - Delayed Quote USD

MiNK Therapeutics, Inc. (INKT)

0.9275 +0.0563 (+6.46%)
At close: April 26 at 4:00 PM EDT
0.9748 +0.05 (+5.10%)
After hours: April 26 at 7:22 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
22,921.1050
22,921.1050
30,949.2780
28,358.5910
10,796.7110
Operating Income
-22,921.1050
-22,921.1050
-30,949.2780
-28,358.5910
-10,796.7110
Net Non Operating Interest Income Expense
463.2560
463.2560
253.3230
-2,431.6140
-2,440.9030
Other Income Expense
-0.0100
-0.0100
2,704.7430
577.4350
-3,001.2840
Pretax Income
-22,457.8590
-22,457.8590
-27,991.2120
-30,212.7700
-16,238.8980
Net Income Common Stockholders
-22,457.8590
-22,457.8590
-27,991.2120
-30,212.7700
-16,238.8980
Diluted NI Available to Com Stockholders
-22,457.8590
-22,457.8590
-27,991.2120
-30,212.7700
-16,238.8980
Basic EPS
-0.65
--
-0.83
-1.16
-0.57
Diluted EPS
-0.65
--
-0.83
-1.16
-0.57
Basic Average Shares
34,359.9450
--
33,672.9270
26,025.4890
28,394.9770
Diluted Average Shares
34,359.9450
--
33,672.9270
26,025.4890
28,394.9770
Total Operating Income as Reported
-22,921.1050
-22,921.1050
-30,949.2780
-28,358.5910
-14,637.1860
Total Expenses
22,921.1050
22,921.1050
30,949.2780
28,358.5910
10,796.7110
Net Income from Continuing & Discontinued Operation
-22,457.8590
-22,457.8590
-27,991.2120
-30,212.7700
-16,238.8980
Normalized Income
-22,457.8590
-22,457.8590
-27,991.2120
-30,568.2850
-16,238.8980
Interest Income
463.2560
463.2560
253.3230
--
--
Interest Expense
--
--
--
2,431.6140
2,440.9030
Net Interest Income
463.2560
463.2560
253.3230
-2,431.6140
-2,440.9030
EBIT
-22,921.1050
-22,921.1050
-30,949.2780
-28,358.5910
-13,797.9950
EBITDA
-22,716.4880
-22,716.4880
-30,827.5290
-28,280.6310
-13,742.9350
Reconciled Depreciation
204.6170
204.6170
121.7490
77.9600
55.0600
Net Income from Continuing Operation Net Minority Interest
-22,457.8590
-22,457.8590
-27,991.2120
-30,212.7700
-16,238.8980
Total Unusual Items Excluding Goodwill
--
--
--
355.5150
--
Total Unusual Items
--
--
--
355.5150
--
Normalized EBITDA
-22,716.4880
-22,716.4880
-30,827.5290
-28,636.1460
-13,742.9350
12/31/2020 - 10/15/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

AGEN Agenus Inc.
11.69
+40.84%
 
PTIX Protagenic Therapeutics, Inc.
1.3850
-4.48%
 
IKT Inhibikase Therapeutics, Inc.
1.7100
-8.06%
 
MBIO Mustang Bio, Inc.
0.3161
-11.58%
 
LIXT Lixte Biotechnology Holdings, Inc.
3.2600
+0.31%
 
MGNX MacroGenics, Inc.
14.56
+1.32%
 
XLO Xilio Therapeutics, Inc.
1.0900
+7.92%
 
ATHE Alterity Therapeutics Limited
2.5100
+9.61%
 
CTMX CytomX Therapeutics, Inc.
1.5900
-0.62%
 
ALZN Alzamend Neuro, Inc.
0.7195
-0.90%